Overview

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Status:
Withdrawn
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with recurrent and metastatic CRC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImmunityBio, Inc.
NantCell, Inc.
Treatments:
Avelumab
Bevacizumab
Capecitabine
Cetuximab
Cyclophosphamide
Fluorouracil
Fulvestrant
Leucovorin
Nivolumab
Oxaliplatin
Paclitaxel
Vaccines